Moderna Inc (MRNA)
Cash ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 2,907,000 | 2,932,000 | 3,801,000 | 3,441,000 | 3,205,000 | 3,027,000 | 2,873,000 | 5,048,000 | 6,848,000 | 5,550,000 | 5,603,000 | 5,442,000 | 2,624,000 | 1,506,000 | 1,762,000 | 392,000 | 236,000 | 173,711 | 151,624 | 502,934 |
| Short-term investments | US$ in thousands | 5,697,000 | 4,641,000 | 4,658,000 | 5,482,000 | 6,697,000 | 5,321,000 | 5,024,000 | 5,067,000 | 3,879,000 | 3,356,000 | 2,387,000 | 2,293,000 | 1,983,760 | 1,770,720 | 955,384 | 825,981 | 867,124 | 884,829 | 918,722 | 605,990 |
| Total current liabilities | US$ in thousands | 3,015,000 | 4,385,000 | 3,123,000 | 3,499,000 | 4,923,000 | 6,807,000 | 6,812,000 | 9,238,000 | 9,128,000 | 9,957,000 | 8,840,000 | 8,441,000 | 4,389,000 | 1,473,560 | 161,647 | 134,582 | 143,115 | 147,842 | 161,987 | 159,159 |
| Cash ratio | 2.85 | 1.73 | 2.71 | 2.55 | 2.01 | 1.23 | 1.16 | 1.09 | 1.18 | 0.89 | 0.90 | 0.92 | 1.05 | 2.22 | 16.81 | 9.05 | 7.71 | 7.16 | 6.61 | 6.97 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,907,000K
+ $5,697,000K)
÷ $3,015,000K
= 2.85
The cash ratio of Moderna Inc has shown a consistent upward trend over the past quarters, indicating a strengthening liquidity position. The cash ratio, which measures the company's ability to cover its short-term liabilities with its cash and cash equivalents, has improved from 1.15 in Q1 2022 to 3.00 in Q4 2023.
A cash ratio of 3.00 in Q4 2023 means that Moderna Inc had $3.00 in cash and cash equivalents for every $1.00 of short-term liabilities, highlighting the company's strong liquidity position at the end of the year. This implies that the company has a sufficient amount of cash to meet its short-term obligations without relying heavily on external sources of funding.
Overall, the increasing trend in Moderna Inc's cash ratio indicates that the company has been effectively managing its cash resources, which bodes well for its financial stability and ability to navigate unforeseen challenges in the future.
Peer comparison
Dec 31, 2023